From Forest to Formulation: The Journey of 10-DAB III in Nepal

In the global oncology landscape, few compounds are as critical—or as difficult to source—as 10-Deacetylbaccatin III (10-DAB III). For oncologists administering chemotherapy and pharma companies synthesizing life-saving drugs, the journey of this molecule begins far from the sterile environment of a lab. It begins in the mid-hill temperate forests of the Nepal Himalayas.

At Evans Life Sciences, we serve as the vital link between these pristine forests and the global pharmaceutical supply chain, ensuring that the precursor for Paclitaxel and Docetaxel is produced with unmatched purity and ethical standards.

1. The Source: The Himalayan Yew (Taxus wallichiana)

The journey begins with the Himalayan Yew, locally known as Lauth Sallo. Growing at altitudes between 1,800m and 3,300m, these trees have evolved complex chemical defenses to survive the harsh mountain climate. Unlike the Pacific Yew (Taxus brevifolia), which requires the destructive harvesting of bark, the Himalayan species allows for a more sustainable approach: needle and twig harvesting.

2. Sustainable Harvesting & Local Impact

Sustainability is the cornerstone of our oncology program. Evans Life Sciences works closely with rural communities in districts like Makwanpur and Sankhuwasabha to implement regenerative harvesting techniques.

• Pruning vs. Felling: By harvesting only the needles and small twigs, we ensure the trees remain healthy and productive for decades.

• Community Stewardship: This process provides a stable, high-value income source for local farmers, transforming them from harvesters into guardians of Himalayan biodiversity.

3. High-Precision Extraction: Isolating the Intermediate

Once the biomass reaches our state-of-the-art facility, the complex task of isolation begins. Extracting 10-DAB III requires a sophisticated multi-stage process:

• Solvent Extraction: Ground needles undergo a precise leaching process to pull the crude taxane fraction.

• Purification: Through advanced chromatography and recrystallization, we isolate 10-DAB III with a purity exceeding 98-99%.

• The Penultimate Step: While 10-DAB III itself is not the final drug, it is the essential "starting material" for the semi-synthesis of Paclitaxel and Docetaxel.

4. Impact: Powering the Global Oncology Supply Chain

Why does this journey matter to a healthcare professional in London, Shanghai, or New York?

• Supply Security: The natural concentration of Paclitaxel in trees is extremely low (0.01%–0.03%). Semi-synthesis from 10-DAB III is the only way to produce these drugs at the scale required by modern oncology.

• Cost Stability: By optimizing the extraction of 10-DAB III in Nepal, Evans Life Sciences helps mitigate the volatility of the global cancer-medicine market.

• Clinical Efficacy: High-purity intermediates lead to high-purity final injections, directly impacting patient outcomes in the treatment of breast, ovarian, and lung cancers.

Conclusion: A Legacy of Healing

Evans Life Sciences is more than a manufacturer; we are a partner in the global effort to make cancer treatment more accessible. Every gram of 10-DAB III we produce carries with it the resilience of the Himalayas and the dedication of our scientists and local farmers.

Next Step for Pharma Partners:

Evans Life Sciences is currently scaling production to meet the growing demand for oncology intermediates. To discuss bulk supply, technical specifications, or sustainability audits, [Contact our B2B Team here].